Management Forum Logo

Presented by
Management Forum

Advanced Pharmacovigilance Training Course

This course will be of maximum benefit to those drug safety professionals who are working both in the clinical and post-marketing safety arena including QA for auditing.

★★★★★ "Yes the trainer was very good! I think that we have received a lot of new information."

18-20 September 2024
+ 9-13 December 2024, 24-26 March 2025, 2-4 July 2025, 6-10 October 2025 »

from £1349

Need help?  Enrol or reserve

Course overview

Pharmacovigilance has undergone rapid regulatory change in recent years, which has resulted in a complex range of safety and risk assessment activities to perform. This three-day course is designed for those with at least two years’ knowledge in drug safety and will provide a comprehensive, yet practical assessment of the main regulations required to produce a compliant reporting company.

Key topics to be addressed:

  • Audits and expectations – risk-based inspections
  • Compliance and drug safety
  • Overview of the PSMF in the EU
  • Product safety reviews – purpose and function (incorporating the latest EU signal analysis requirements)
  • Safety reporting in licensing agreements
  • Developing company core safety information (CCSI) – CIOMS III
  • PSURs – timing, content and the DSUR and the latest ICH E2C (2nd revision requirements)
  • Implications for safety reporting in global clinical trials
  • Risk-benefit determinations
  • Risk management plans (RMPs)

This course is part of our Vigilance training course collection; for information on the basics of PhV, consider taking a look at our beginner-friendly Pharmacovigilance training course.

Benefits of attending

  • Expand your global safety knowledge
  • Enhance your team’s capabilities and compliance in both the regulations and your company’s expectations
  • Help ensure you build and maintain a quality pharmacovigilance department ready for any pharmacovigilance inspection
  • Participate in group workshop sessions and discuss how to apply the legislation to ensure compliance, especially to satisfy regulatory inspections

Who should attend?

This course would be of maximum benefit to those safety professionals who are working both in the clinical and post–marketing safety arena including QA for auditing. The course covers very diverse activities within the safety department and would be advantageous to those who have either multifunction responsibilities or medical directors who manage teams in the various disciplines.

Enrol or reserve

This course will cover:

Due diligence

  • Due diligence on products/companies (partners and acquisitions)
  • Due diligence involvement – team composition
  • Safety information requirements for due diligence
  • Review of safety data (clinical and post-marketing)
  • Defining risk in due diligence appraisals

Training for drug safety reporting duties

  • Regulations concerning safety training
  • Who trains whom and when?
  • Training versus job description
  • Training records, maintenance and updates
  • Role of QA and HR in training

Audits and expectations

  • Regulatory expectations in pharmacovigilance audits (risk-based inspections)
  • Preparation for the audit
  • Records to be available at the audit
  • Audit findings/recommendations

Compliance and drug safety

  • Basic principles – what will the regulators want to see?
  • Measuring compliance
  • Quality versus quantity in safety reports
  • Future aspects in ensuring efficient compliance
  • Quality management under the new EU legislation


  • The PSMF – purpose and maintenance
  • The PSMF annexes
  • The PSMF and audits

Interactive exercise: The requirements for a safety department

Product safety reviews – purpose and function

  • The Safety Review Committee (SRC)
  • What to look for in signal evaluation under latest EU guidance
  • Timings for safety review in clinical and post-marketed products
  • Record keeping for safety review meetings
  • Serious safety findings – crisis management following new safety findings

Interactive exercise: designing the requirements for a safety review group

Safety reporting in licensing agreements

  • What types of licensing agreements exist?
  • What are the EU and FDA regulations concerning licensing agreements?
  • Audits of pharmacovigilance capabilities in licensing partners
  • What agreements need to be in place for safety reporting?
  • Safety reporting agreements – what needs to be covered?
  • Monitoring safety agreements – what happens if it goes wrong?

Developing CCSI – CIOMS III

  • Developmental core safety information (DCSI)
  • How to determine what to include and what to exclude in DCSI/CCSI
  • Are there differences in EU and FDA?
  • Maintenance and development of CCSI

Interactive exercise: should new safety data from a clinical trial be put into core safety information?

PSURs and the revisions in ICH E2C

  • Timing for PSURs
  • PSUR content and latest format
  • Late breaking information and PSUR extensions
  • The DSUR

The EU Clinical Trials Directive

  • The principles of the Directive
  • Implications for safety reporting in global clinical trials
  • The SUSAR database
  • The EUDRACT database
  • The new EU clinical trial regulation

Risk-benefit determinations

  • Definitions of risk-benefit – FDA and EU perspective
  • Risk-benefit assessments – who does this and where does the information go?
  • Safety assessments and risk-benefit – frequency and reporting
  • Changes in risk-benefit – how to manage and review existing profiles

Interactive exercise: reviewing the safety and risk-benefit of a product


  • Purpose
  • Content
  • Monitoring and updating the RMP
  • Reporting the RMP

Crisis management within drug safety

  • Regulations and guidelines in connection with serious safety issues
  • What determines a crisis?
  • Communications to regulators – what is required?
  • Communications within the company
  • What happens next?

Interactive exercise: deciding how to handle a major crisis within the company

Delegates will be split into groups and present what they need to have in place in order to effectively manage the crisis and look to its resolution.

Enrol or reserve

Graeme Ladds
PharSafer Associates Ltd

Graeme Ladds, Director of PharSafer, has over 30 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

More details

NEW higher discounts for multiple bookings - bring your colleagues to make your training budget go further:

  • 30% off the 2nd delegate*
  • 40% off the 3rd delegate*
  • 50% off the 4th delegate*

Please contact us for pricing if you are interested in booking 5 or more delegates

18-20 September 2024

Live online

09:00-16:30 UK (London) (UTC+01)
10:00-17:30 Paris (UTC+02)
04:00-11:30 New York (UTC-04)
Course code 13888

  • GBP 1,349 1,649
  • EUR 1,939 2,359
  • USD 2,201 2,669

Until 14 Aug

View basket 

Not ready to book yet?

for 7 days, no obligation

9-13 December 2024

Live online

13:00-17:15 UK (London) (UTC+00)
14:00-18:15 Paris (UTC+01)
08:00-12:15 New York (UTC-05)
Course code 14096

  • GBP 1,349 1,649
  • EUR 1,939 2,359
  • USD 2,201 2,669

Until 04 Nov

View basket 

Not ready to book yet?

for 7 days, no obligation

24-26 March 2025

Live online

09:00-16:30 UK (London) (UTC+00)
10:00-17:30 Paris (UTC+01)
05:00-12:30 New York (UTC-04)
Course code 14605

  • GBP 1,349 1,649
  • EUR 1,939 2,359
  • USD 2,201 2,669

Until 17 Feb

View basket 

Not ready to book yet?

for 7 days, no obligation

2-4 July 2025

Rembrandt Hotel

09:00-17:00 UK (London)
Course code 14724
Optional £270/€351/$405 per night

  • GBP 1,699 1,999
  • EUR 2,449 2,869
  • USD 2,801 3,269

Until 28 May

  • 3 days classroom-based training
  • Optional accommodation - 3 nights including breakfast, checking in the day before the course
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy

View basket 

Not ready to book yet?

for 7 days, no obligation

6-10 October 2025

Live online

13:00-17:15 UK (London) (UTC+01)
14:00-18:15 Paris (UTC+02)
08:00-12:15 New York (UTC-04)
Course code 15137

  • GBP 1,349 1,649
  • EUR 1,939 2,359
  • USD 2,201 2,669

Until 01 Sep

View basket 

Not ready to book yet?

for 7 days, no obligation

* Early booking discounts may not be combined with other discounts or offers. As such, the discounts for 2nd/3rd/4th delegates are based on the full price; and apply only when booking multiple delegates on the same date.

Reviews of IPI's Advanced Pharmacovigilance training course

Yes the trainer was very good! I think that we have received a lot of new information.

Dec 11 2023

Styliani Katsarou
Quality Consultant, Scandinavian Regulatory Services

Sep 20 2023

Practical knowledge of situations in Industry and the slides contained enough information to obtain a good understanding of an area that is complicated. the webinar was excellent, the speaker was very familiar with the most recent legislation

Martina Lee
Regulatory Affairs Specialist, NorthStar

Sep 20 2023

I really enjoyed the course and took a lot out of it. The real life examples were really helpful.

Joana Pereira
Senior RA Manager, Cycle Pharmaceuticals Ltd

Jun 7 2023

In my overall opinion, the course was excellent in terms of content, organisation and presentation. The content was well-structured, comprehensive, and covered relevant topics that were of interest to me. The material was presented in a clear and organised manner, making it easy to follow and understand. I would highly recommend this course to others seeking to gain knowledge in the subject matter.

Mareike Vogt
Senior Associate Patient Safety & Consumer Service, Omega Pharma Deutschland GmbH

Jun 7 2023

great course

Omar H. AlAnazi
Control and Alarm Specialist 2 - Pharmacovigilance, Saudi Food & Drug Authority

Jun 7 2023

Excellent speaker. I do really respect his knowledge

Abdulaziz N Alakeel
Alert and Controling Specialist I, Saudi Food & Drugs Authority

Mar 22 2023

Very lively presentation, not at all a dull workshop. I Will recommend it as it was very good

Bettina Bannert
Doctor, Universitätsspital Basel/ Department Klinische Forschung

Mar 22 2023

Very wide topic, yet concise and understandable

Marko Laginja
PV deputy, Providens d.o.o.

Sep 20 2023

Was so good

Hammad A Al Dali
Expert in Pharmacovigilance System Inspection, Saudi Food & Drugs Authority

Mar 22 2023

Very satisfied with the material provided, manner of delivery and content discussed.

Matthew Zarb
Pharmacovigilance Scientist & Responsible Person , Eugia Pharma (Malta) Ltd

Mar 1 2022

This course is one of the best Pharmacovigilance course where you can discuss the complex issues, speaker has strong PV background and tremendous knowledge... Course is just perfect.

Sagar Lamichhane
Sr. Pharmacovigilance Specialist, GE Healthcare

Mar 1 2022

I really enjoyed the webinar, very informative and the speaker was very knowledgeable and put you at ease. I feel more confident in my role.

Shelley Browning
Regulatory and PV Manager, Weleda

Mar 1 2022

Fantastic speaker! Well-paced, informative, stayed on schedule, answered questions, provided valuable anecdotes from his experiences. I learned and absorbed MUCH more in this webinar than for ex. the Intro. Pharmacovigilance that was in person with multiple speakers.

Sarah Yandura
Global Safety Specialist, LEO PHARMA

Mar 1 2022

Fantastic - I would recommend this course to all in this field of work.

Jenny Hipwell
Pharmacovigilance Manager, MSD Animal Health UK Ltd

Sep 21 2022

I was hoping to broadening my PV knowledge in the human area and to be able to compare with my knowledge in veterinary PV. I thought the subjects were perfect and lever also good (not too easy).

Sarah Bodeby
Pharmacovigilance Specialist, PharmaRelations AB

Sep 21 2022

He (Graeme Ladds) is a very experienced professional and his practical examples of inspections' findings in companies were really useful to understand what the main faults are.

Maria Sampaio
Associate Pharmacovigilance and Drug Safety Manager, BIAL - Portela & Cª, S.A.

Dec 1 2021

It was very informative and really useful training for PV professionals

Viranchi Desai
Senior Manager , Gilead Science

Dec 1 2021

Graeme was really excellent, although a lot of slides he managed to keep me focused for all those hours with his stories from interactions with CA and MAH. So interesting. That is what you need, examples from the real world. The interactive sessions were also much appreciated. I feel that I got it all! However, another course with Graeme is now on my list.

Åsa Kjellström
Pharmacovigilance Senior Safety Scientist, Calliditas Therapeutics AB

Mar 17 2021

Really good speaker, lots of examples of scenarios which helps. Allowed interaction between the delegates to discuss topics during exercises.

Rebecca Brennan
Safety Advisor, Alliance Healthcare Ltd

Mar 17 2021

Inspiring speaker. I was very excited about all the anecdotes that he told. Overall a very rewarding course.

Helle Ribjerg
Global Safety Specialist, LEO Pharma

Mar 17 2021

Very good webinar. Well structured, interactive questions, small group, advanced topics (not easy to find elsewhere), competent speaker, good platform.

Bettina Isler
Medical Information Manager, OrPha Swiss GmbH

Sep 23 2020


Sidse Schjøtz
Complinace Manager, ALK

Sep 23 2020

Very nice course - will recommend to colleagues

Tina Rishoej Clausen
Global Safety Specialist, LEO Pharma

Sep 23 2020

Good course and the leader was very clear in what he wanted to say. Exercises were fun..

Amrita Kang
drug safety scientist, GE healthcare

Sep 23 2020

Generally very good and good to have the anecdotes from real life.

Sanne Mathias
Head of Compliance, ALK

Sep 23 2020

Parts of the presentation especially Day 3 were informative as it was more tailored to my role. I enjoyed the talk of RMPs, PSURs and crisis management. A lot of basics however were covered in this 'advanced course' in the CT directive topic, would be nice just to state what's changed and what's not changed almost like presenting a gap analysis, instead of covering basic definitions such as definition of an SAE and SUSAR and investigator reporting timelines. There was a 2 minute discussion on Brexit related changes on Day 2 which could have been a formal session as a presentation as I found that very useful for my role.

Maria Sajid
Safety Evaluation Scientist, Eisai Europe Ltd

Sep 25 2019

Overall, the best seminar I've attended in format, topics, and speaker. I had hoped to learn about PV in general and all the different reporting requirements and report types – I learned much more than that. The speaker was great and I particularly liked the real-life stories and examples.

Jane Bateman
Senior Drug Safety Scientist, GE Healthcare

Sep 25 2019

I was hoping to get more knowledge about the topics listed in the course presentation and I actually got a lot more, as we were not only given information related to the legislation in force but also very useful examples of applicability and some non-compliance cases. The speaker is undoubtedly an expert in the field with excellent presentation skills of all the proposed topics, including the most complex ones from a regulatory point of view. His experience and his analytic method facilitated my understanding of some critical passages of the law.

Ilaria Gargano
Global Safety Specialist, Leo Pharma

Mar 25 2019

The speaker shared a lot of knowledge and experiences which put in context the regulation/expectations from agencies and made the course really interesting.

Audrey Dicaire-Lavigne
Pharmacovigilance Leader, Jubilant Draximage Inc.

Mar 25 2019

The speaker had really extensive knowledge and he was able to transmit all the topics in a very clear way.

Elena Jiménez Gutiérrez
Global Safety Professional, LEO Pharma

Mar 25 2019

Great presentations, great time keeping, good balance between exercises and presentations

Ida Mizera
Local Responsible Person for PV, Grunenthal Ltd

Mar 25 2019

Graeme has superb knowledge of the regulations and guidelines around pharmacovigilance and talks in a passionate and engaging manner. An excellent course that really gives the students a much better understanding of pharmacovigilance and the opportunity to share knowledge. The content was spot on and Graeme's presentation style was engaging.

Christopher Harper
Senior Medical Information Manager, Astellas Pharmaceuticals

Sep 25 2019

The speaker was able to make a dry topic really exciting and I particularly liked the interaction with the group.

Margot Börgartz
Stewardship Manager, Bayer AG

Sep 25 2019

[Graeme] was a very good presenter with very good industry knowledge and experience. Very interactive sessions and answered all our questions.

Smitha Bhat
Principal CMG Scientist, GlaxoSmithKline

Mar 25 2019

Very valuable with real examples. I liked that future elements of PV regulation were pointed out and not just the current one.

Dorthe Lundmark
Drug Safety Coordinator, Pharmacosmos A/S

Mar 25 2019

The content of the course was excellent for an all round view of PV, the presentations were good and flowed from one aspect of PV to another. Graeme's passion and energy for drug safety was evident throughout the three days. I really enjoyed this course.

Ciara Walsh
Head of Regulatory Affairs and Pharmacovigilance, Noden Pharma DAC

Mar 7 2018

Amazing for continuing to develop skills in PV to keep up with the regulatory expectations.

Maria Calvo Subirats
GCP&GVP Responsible (QA Unit), Ferrer Internacional

Mar 7 2018

The presenter managed to keep our attention and shared concrete examples, which helped us to clearly understand what's relevant.

Faouria Dervisagic
Drug Safety Associate, Idorsia Pharmaceuticals Ltd

Mar 7 2018

Was great, will support my work

Anette Wolfmeyer
Deputy QPPV (Qualified Person for Pharmacovigilance), Bayer Animal Health GmbH

Mar 7 2018

Excellent course - taught me from A to Z about PV. Content well coordinated to capture audience with different levels of PV experience. Excellent speaker. Highly recommended.

Suna Horner
Associate Medical Manager, HRA Pharma UK & IE Ltd.

Mar 7 2018

Very good speaker

Nicolas Vauche
Drug Safety Officer, AnticipSante

Mar 7 2018

This course provides a great opportunity to gain understanding of latest updated on the PV regulatory requirements and the expectation from regulatory inspectorate.

Maria Calvo Subirats
GCP&GVP Responsible (QA Unit), Ferrer Internacional

Sep 24 2018

A very knowledgeable and experienced speaker always ready to answer all the questions and give real-life examples.

Darya Pospíšilová
Pharmacovigilance Project Manager, Arriello

Sep 24 2018

The course was thorough and the manual a good resource to refer back to. The speaker had a very engaging presentation style and freely answered questions and shared real-word examples and inspection expectations.

Katy Blake
PV Specialist , Dexcel Pharma Limited

Sep 24 2018

A PV overview in three days, that's nice.

Tina Pank Vase
Associate Professional, LEO Pharma A/S

Mar 7 2018

Content, presentation and speaker were just great.

Wendy Kleijberg
QPPV, Baggerman Farma Consult

Mar 7 2018

It covers a lot of subjects, it was a complete course regarding activities in Pharmacovigilance. Presentation and speakers were really clean.

Gwladys Becuwe
Drug Safety Officer, Anticipsante

Sep 25 2017


Olga Orlova
PV Process Manager, Bayer, JSC

Sep 25 2017

Good content and put into real life context

Tony Rigden
Head Of Regulatory & Pharmacovigilance, Chiesi UK LTD

Sep 25 2017

Very interesting and interactive course. Good training material and a competent trainer

Francesca Romana Borgia
PV QA Specialist & Auditor, Chiesi

Sep 25 2017

Graeme is clearly a PV Expert. The content of training gave a very good overview of all aspects of PV. Finally, a course that you can use in your daily work-life.

Thea Ellermann Petersen
Senior Pharmacovigilance Specialist, LEO Pharma

Mar 6 2017


Mona Bjørkmo
Pharmacovigilance Scientist, GE Healthcare AS

Mar 6 2017

Very good (advanced) course

Peter Kohut
PV Specialist, Ewopharma International, s.r.o.

Mar 6 2017

Very experienced in many areas relevant for PV. Good examples. Open for questions and discussions.

Ingvild Haugen
PV Scientist, GE Healthcare

Mar 6 2017

Very good speaker with a wealth of knowledge. Good examples and real life stories. Would like other activities rather than pure listening.

Lisa Courtier
Drug Safety Officer, JensonR+ Limited

Sep 28 2016

Trainer is excellent

Murugan Addepalli
Senior Research Scientist, Sun Pharmaceutical Industries Ltd

Sep 28 2016

Content - highly relevant to my position. Presentation - enough detail and to the point. Speaker - very knowledgeable and engaging

Saha Jasarevic
Global Pharmacovigilance Scientist, GE Healthcare AS

Sep 28 2016

Overall a very positive experience, the course covers very current and relevant topics, is well organised and presenter is an engaging speaker

Rita Bildøy
PV Compliance and Training Expert, Ge Healthcare Lifesciences

Sep 28 2016

Really beneficial -Graeme is the best

Trine Allerslev
Senior Pharmacovigialnce Specialist, LEO Pharma

Sep 28 2016

I am really happy with all of it

Jelena Rebernisak
TPC Operations Coordinator, Pliva Croatia Ltd.

Sep 28 2016

More examples would be very helpful.

Jung Hyun Byun
PV Associate, Dong-A ST Co.,Ltd

United Kingdom

  • Abbott Healthcare Products Ltd
  • Actavis
  • Adamas Consulting Ltd
  • Alliance Healthcare Ltd
  • Almirall Limited
  • APC Pharma
  • Ark Therapeutics Ltd
  • Astellas Pharmaceuticals
  • AstraZeneca UK Ltd
  • Auden McKenzie Group
  • Biogen IDEC Ltd
  • Boehringer Ingelheim Ltd
  • Boots
  • Britannia Pharmaceuticals Ltd
  • British American Tobacco (Investments) Limited
  • Cancer Research UK
  • Cardinal Health
  • Celgene Europe Ltd
  • Chiesi Limited
  • Chiesi UK LTD
  • Chugai Pharma Europe Ltd
  • Cycle Pharmaceuticals Ltd
  • Dexcel Pharma Limited
  • Diamond Pharma Services
  • Eisai Europe Limited
  • Eisai Europe Ltd
  • Eisai Limited
  • Eli Lilly & Co Ltd
  • Ewopharma International s.r.o.
  • Forest Laboratories UK Ltd
  • Genethics Regulatory Services
  • Genus Pharmaceuticals Ltd
  • Gilead Science
  • Gilead Sciences
  • GlaxoSmithKline
  • Grunenthal Ltd
  • GW Pharmaceuticals
  • GW Pharmaceuticals plc
  • Hospira UK Limited
  • HRA Pharma UK & IE Ltd.
  • Icon Clinical Research (UK) Limited
  • Idis Limited
  • Inceptua
  • Innovata Ltd (part of Vectura Group plc)
  • Ipsen Biopharm Ltd
  • Janssen Cilag Ltd
  • Janssen-Cilag Ltd
  • Jazz Pharmaceuticals
  • JensonR+ Limited
  • Johnson & Johnson Consumer Services EAME Ltd
  • KKI
  • Kowa Research Europe Ltd
  • Liverpool School of Tropical Medicine
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Merck Serono Ltd
  • Merck Sharp & Dohme Ltd
  • Mercury Pharma Management Services Ltd
  • MSD Animal Health UK Ltd
  • Mundipharma Research Ltd
  • Napp Pharmaceutical Group Ltd
  • Norgine Ltd
  • Norgine Ltd.
  • Novartis Pharmaceuticals UK Ltd
  • Novo Nordisk Ltd
  • Nycomed UK Limited
  • Ono Pharma UK Ltd
  • Parexel International Ltd
  • Perrigo
  • Pfizer Limited
  • Piramal Healthcare Ltd
  • Procter & Gamble Technical Centres Ltd
  • Proctor & Gamble Technical Centres Ltd
  • ProductLife Limited
  • ProductLife Ltd
  • Pure Drug Safety
  • Queen Anne Street Medical Cent
  • Ranbaxy Laboratories Ltd
  • RB
  • Reckitt Benckiser Healthcare (UK) Ltd
  • Roche
  • Roche Products Ltd
  • Roche Products Ltd.
  • Rosemont Pharmaceuticals
  • Rosemont Pharmaceuticals Limited
  • Sandoz Limited
  • SEQ Limited
  • Shire Pharmaceutical Ltd
  • Smith & Nephew Wound Management
  • Spectrum Regulatory Solutions
  • Stiefel Labs (Maidenhead) Ltd
  • Syntaxin Ltd
  • Takeda Development Centre Europe Ltd
  • Takeda UK Limited
  • Torbay Pharmaceuticals
  • UCB Pharma Limited
  • Valeant
  • Veterinary Medicines Directorate
  • Warner Chilcott Pharmaceuticals UK Ltd
  • Weleda
  • Winthrop Pharmaceuticals UK Ltd
  • Wyeth Pharmaceuticals


  • Actavis A/S
  • AJ Vaccines A/S
  • ALK
  • ALK Abello A/S
  • Amgros
  • Astellas Pharma A/S
  • Billev Pharma ApS
  • Ferring Pharmaceuticals A/S
  • H. Lundbeck A/S
  • Klifo
  • LEO Pharma
  • Leo Pharma A/S
  • LEO Pharrma
  • Novo Nordisk
  • Novo Nordisk A/S
  • Pharma Nord ApS
  • PharmaChem Consulting
  • Pharmacosmos A/S
  • Statens Serum Institut
  • Takeda Pharma A/S
  • VAN Pharma Consult


  • Amgen
  • AnticipSante
  • AnticipSante SAS
  • Besins Healthcare France
  • Boehringer Ingelheim France
  • Debioclinic SA
  • Ethypharm
  • Galderma R&D
  • Guerbet
  • Janssen
  • Johnson & Johnson
  • Orphan Europe
  • Pierre Fabre Medicament
  • Sanofi Pasteur MSD
  • Sanofi Pasteur Siege mondial
  • Service Comptabilité
  • Stallergenes Greer plc
  • Substipharm


  • Abbott Laboratories GmbH
  • Abbott Products GmbH
  • Bayer Animal Health GmbH
  • Bayer Pharma AG
  • Berlin-Chemie AG
  • Cheplapharm Arzneimittel
  • Fresenius Kabi Oncology Limited
  • Grunenthal GmbH
  • Life Molecular Imaging GmbH
  • Merck KGaA
  • Merck Serono
  • MSD AH Innovation GmbH
  • Mundipharma Research GmbH & Co Kg
  • Mylan Healthcare GmbH
  • Omega Pharma Deutschland GmbH
  • Schwarz BioSciences GmbH
  • Solvay Deutschland GmbH
  • UCB Pharma GmbH


  • Acino Pharma AG
  • Actelion Pharmaceutical Ltd
  • Basilea Pharmaceutica International Ltd
  • Celgene
  • Covis Pharma
  • CSL Behring AG
  • F. Hoffmann-La Roche Ltd
  • Ginsana SA
  • HPM (Geneva) SA
  • IBSA, Institut Biochimique SA
  • Idorsia Pharmaceuticals Ltd
  • Medicines for Malaria Venture
  • Novartis Pharma AG
  • OrPha Swiss GmbH
  • Roche Pharma (Switzerland) Ltd
  • Universitätsspital Basel/ Department Klinische Forschung
  • Vifor SA


  • Aspen Pharma Trading Ltd
  • Astellas Pharma
  • Chanelle Medical
  • Helsinn Birex Pharmaceuticals Ltd
  • Noden Pharma DAC
  • NorthStar
  • NorthStar Healthcare Ltd
  • Pfizer Limited
  • Pharmaceutical Development Ireland Limited
  • Pinewood Healthcare Ltd.
  • PPD
  • Shandon McGee Pharmacovigilance Company


  • Almirall S.A.
  • Atlanta Agencia de Viajes S.A.
  • Bayer Hispania SL
  • CSL Behring SA
  • Ferrer Internacional
  • Grupo Ferrer Internacional SA
  • Grupo Ferrer Internaional S.A.
  • Grupo Ferrer International
  • Laboratorios Almirall S A
  • Pharma Mar SA
  • Pharma Mar, S.A.
  • PharmaMar

United States of America

  • AEMS
  • Aeras Global TB Vaccine Foundation
  • Bausch & Lomb Inc
  • CareFusion
  • Chiesi USA
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Genentech Inc
  • Hoffmann-La Roche Incorporated
  • Medivation


  • Amgen NV
  • Certor bvba
  • Colgate-Palmolive R&D
  • Glaxo Smithkline Biologicals
  • GlaxoSmithKline Vaccines
  • Janssen Pharmaceutica NV
  • Nikkiso Belgium
  • Procter & Gamble Pharmaceuticals
  • SGS Belgium NV
  • SGS Belgium NV Life Science Services
  • UCB Pharma SA


  • Astellas BV
  • Baggerman Farma Consult
  • Baggerman Farma Consult B.V.
  • Dada Consultancy BV
  • Eurocept B.V.
  • Genzyme Europe BV
  • HAL Allergy BV Leiden
  • Interdos
  • Interdos Pharma bv
  • Merck Sharp & Dohme
  • N V Organon


  • Recordati S.p.A.
  • Alfa Wassermann S.p.A.
  • Alfasigma spa
  • Alfrapharma Srl
  • Angelini Pharma S.p.A.
  • Chiesi
  • Di Renzo SRL
  • Recordati S.p.A
  • Recordati S.p.A.


  • AGA AB
  • AstraZeneca
  • AstraZeneca AB
  • AstraZeneca R&D Lund
  • Calliditas Therapeutics AB
  • PharmaRelations AB
  • Sanofi-aventis AB
  • Scandinavian Regulatory Services
  • SOBI
  • TFS, trial form support


  • Agency for Medicinal Products and Medical Devices of Croatia (HALMED)
  • Belupo d.d.
  • Farmal D.D.
  • Pliva Croatia Ltd
  • Pliva Croatia Ltd.
  • Prime Vigilance doo Zagreb
  • Providens
  • Providens d.o.o.


  • Baxter AG
  • Baxter Innovations GmbH
  • Boehringer Ingelheim
  • Boehringer Ingelheim RCV GmbH & Co KG
  • Octapharma Pharmazeutika Produktionsges.m.b.H
  • Octapharma Pharmazeutika Produktionsges.m.b.H.
  • Valneva Austria GmbH

Czech Republic

  • Arriello
  • Arriello s.r.o.
  • PPD
  • Teva Czech Industries S R O
  • Zentiva ks


  • Actavis
  • Alvogen Romania SRL
  • Ewopharma AG
  • Romastru Trading Srl
  • Worwag Pharma GmbH & Co. KG

Saudi Arabia

  • mundipharma ksa
  • Saudi Food & Drugs Authority
  • Saudi Food and Drug Authority
  • SFDA


  • ApoPharma Inc
  • Jubilant Draximage Inc.
  • Theratechnologies inc


  • Kamada Ltd.
  • NeuroDerm
  • TEVA


  • CSL Biotherapies
  • CSL Limited
  • Roche Products Pty Ltd


  • Delorbis Pharmaceuticals Ltd
  • Genesis Pharma (Cyprus) Ltd
  • Medochemie Limited

Korea, Republic Of

  • GC Biopharma
  • Green Cross Corp.
  • MedPacto


  • GE Healthcare
  • GE Healthcare AS
  • Ge Healthcare Lifesciences


  • Bayer, JSC
  • Sanofi
  • Voyage Tour LLC

Slovak Republic

  • Ewopharma International s.r.o
  • Ewopharma International, s.r.o.
  • Viatris Slovakia s.r.o.


  • Bayer Turk Kimya San. Ltd. Sti
  • Boehringer Ingelheim Ilaç Tic. A.S.
  • Nobel Ilac Sanayii ve Ticaret A.S A


  • Amgen
  • AstraZeneca do Brasil Ltda.


  • PPD, part of Thermo Fisher Scientific
  • Qualitis


  • Solvay Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd


  • Eisai Co. Ltd
  • Takeda Pharmaceutical Company Ltd


  • Pharmaniaga Logistics Sdn Bhd


  • APL Swift Services (Malta) Ltd
  • Eugia Pharma (Malta) Ltd


  • BIAL - Portela & Cª, S.A.
  • Sanofi-Aventis SA


  • Poslovni centar Hemofarm

South Africa

  • Aspen Pharmacare Holdings

United Arab Emirates

  • Gulf Pharmaceutical Industries
  • Pfizer Gulf FZ LLC


  • Medica SA


  • Celgene Kft

Korea, Democratic People's Republic Of

  • Dong-A ST Co.,Ltd


  • United Laboratories Inc


  • Medis, d.o.o.


  • Schering-Plough CE AG

Enrol or reserve

Run Advanced Pharmacovigilance Live online/Classroom for your team

3 days

Typical duration

Pricing from:

  • GBP 1,200
  • Per attendee, based on 10 attendees
  • Course tailored to your requirements
  • At your choice of location, or online


We can customise this course to your requirements and deliver it on an in-house basis for any number of your staff or colleagues.

Contact our in-house training experts Aleksandra Beer and Yesim Nurko to discuss your requirements:

Multiple colleagues? See above for details of our discounts for 2, 3, or 4 delegates. For more, talk to one of our training experts to discuss how to:

Run this course conveniently and cost-effectively in-house for your staff and colleagues

Aleksandra Beer

Aleksandra BEER
Training expert

Yesim Nurko

Training expert

+44 (0)20 7749 4749